SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Area of Science:

• Hematology
• Immunology
• Infectious Diseases
• Vaccinology

Background:

• Patients with hematologic conditions possess heightened vulnerability to severe COVID-19 and associated mortality.
• This increased risk stems from immune deficiencies inherent to hematologic disorders or their treatments.

Purpose of the Study:

• To evaluate the immunogenicity of COVID-19 vaccination in patients with hematologic conditions.
• To assess the induction of antibody and cellular immune responses following vaccination in this patient cohort.

Main Methods:

• Analysis of prospective vaccine immunogenicity studies.
• Assessment of antibody concentrations and cellular immune responses post-vaccination.
• Consideration of B cell depletion impact on humoral immunity.

Main Results:

• A 3-dose COVID-19 vaccination schedule generally yields antibody concentrations comparable to healthy adults receiving 2 doses.
• While humoral responses are diminished in B cell depleted patients, vaccination still elicits robust cellular immunity.
• The long-term protective effect of 3-dose schedules and boosters against severe COVID-19 in these patients requires confirmation.

Conclusions:

• Three-dose COVID-19 vaccination regimens induce significant immune responses in most patients with hematologic conditions.
• Cellular immunity is notably induced even in B cell depleted patients, suggesting a potential benefit.
• Population-based studies are essential to confirm the real-world effectiveness of these vaccination strategies against severe COVID-19 outcomes.